References
- Gonen Y, Balakier H, Powell W, et al. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990;71:918–22.
- Fatemi HM, Polyzos NP, van Vaerenbergh I, et al. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone–gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2013;100:742–7.
- Lawrenz B, Garrido N, Samir S, et al. Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation. PLoS One 2017;12:e0176600.
- Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005;20:1213–20.
- Hutchison JS, Zeleznik AJ. The corpus luteum of the primate menstrual cycle is capable of recovering from a transient withdrawal of pituitary gonadotropin support. Endocrinology 1985;117:1043–9.
- Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009;18:630–4.
- Seyhan A, Ata B, Polat M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013;28:2522–8.
- Chen ZJ, Shi Y, Sun Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med 2016;375:523–33.
- Kol S, Breyzman T, Segal L, et al. 'Luteal coasting' after GnRH agonist trigger - individualized, HCG-based, progesterone-free luteal support in 'high responders': a case series. Reprod Biomed Online 2015;31:747–51.
- La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014;20:124–40.
- Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112–20.
- Csapo AI, Pulkkinen MO, Kaihola HL. The relationship between the timing of luteectomy and the incidence of complete abortions. Am J Obstet Gynecol 1974;118:985–9.
- Jordan J, Craig K, Clifton DK, et al. Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil Steril 1994;62:54–62.
- Tavaniotou A, Smitz J, Bourgain C, et al. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 2000;6:139–48.
- Liu HC, Pyrgiotis E, Davis O, et al. Active corpus luteum function at pre-, peri- and postimplantation is essential for a viable pregnancy. Early Pregnancy 1995;1:281–7.
- Aslih N, Ellenbogen A, Shavit T, et al. Can we alter pregnancy outcome by adjusting progesterone treatment at mid-luteal phase: a randomized controlled trial. Gynecol Endocrinol 2017;9:1–5.
- Hull MG, Savage PE, Bromham DR, et al. The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle (“ovulation”) derived from treated and untreated conception cycles. Fertil Steril 1982;37:355–60.